Tecentriq®
PD-L1 inhibitor
1200 mg intravenously (IV) every 3 weeks
1680 mg IV every 4 weeks
840 mg, 1200 mg, and 1680 mg.
1st infusion over 60 minutes, then subsequent infusions over 30 minutes if no infusion related reactions (IRRs) with 1st dose.
840 mg and 1200 mg vials (60 mg/mL)
Flat dose-response and dose-toxicity relationship (PD-L1 or PD-1 inhibitors)
27 days (135 days)
None.